354 related articles for article (PubMed ID: 27806574)
1. Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis.
Penning TM
Chem Res Toxicol; 2017 Jan; 30(1):162-176. PubMed ID: 27806574
[TBL] [Abstract][Full Text] [Related]
2. Enhanced 4-hydroxynonenal resistance in KEAP1 silenced human colon cancer cells.
Jung KA; Kwak MK
Oxid Med Cell Longev; 2013; 2013():423965. PubMed ID: 23766854
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.
Tebay LE; Robertson H; Durant ST; Vitale SR; Penning TM; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2015 Nov; 88(Pt B):108-146. PubMed ID: 26122708
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductases and bioactivation/detoxication.
Jin Y; Penning TM
Annu Rev Pharmacol Toxicol; 2007; 47():263-92. PubMed ID: 16970545
[TBL] [Abstract][Full Text] [Related]
5. Identification of aldo-keto reductases as NRF2-target marker genes in human cells.
Jung KA; Choi BH; Nam CW; Song M; Kim ST; Lee JY; Kwak MK
Toxicol Lett; 2013 Mar; 218(1):39-49. PubMed ID: 23305850
[TBL] [Abstract][Full Text] [Related]
6. Aldo-Keto Reductases and Cancer Drug Resistance.
Penning TM; Jonnalagadda S; Trippier PC; Rižner TL
Pharmacol Rev; 2021 Jul; 73(3):1150-1171. PubMed ID: 34312303
[TBL] [Abstract][Full Text] [Related]
7. Saturated and aromatic aldehydes originating from skin and cutaneous bacteria activate the Nrf2-keap1 pathway in human keratinocytes.
Ron-Doitch S; Soroka Y; Frusic-Zlotkin M; Barasch D; Steinberg D; Kohen R
Exp Dermatol; 2021 Oct; 30(10):1381-1387. PubMed ID: 32347981
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.
Panieri E; Saso L
Antioxid Redox Signal; 2021 Jun; 34(18):1428-1483. PubMed ID: 33403898
[No Abstract] [Full Text] [Related]
9. Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
MacLeod AK; Acosta-Jimenez L; Coates PJ; McMahon M; Carey FA; Honda T; Henderson CJ; Wolf CR
Br J Cancer; 2016 Dec; 115(12):1530-1539. PubMed ID: 27824809
[TBL] [Abstract][Full Text] [Related]
10. The cytoprotective role of the Keap1-Nrf2 pathway.
Baird L; Dinkova-Kostova AT
Arch Toxicol; 2011 Apr; 85(4):241-72. PubMed ID: 21365312
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
12. The Role of NRF2/KEAP1 Signaling Pathway in Cancer Metabolism.
Song MY; Lee DY; Chun KS; Kim EH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922165
[TBL] [Abstract][Full Text] [Related]
13. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
14. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
[TBL] [Abstract][Full Text] [Related]
15. Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver.
Wu KC; Cui JY; Klaassen CD
PLoS One; 2012; 7(7):e39006. PubMed ID: 22808024
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
17. Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
Palackal NT; Lee SH; Harvey RG; Blair IA; Penning TM
J Biol Chem; 2002 Jul; 277(27):24799-808. PubMed ID: 11978787
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds.
MacLeod AK; McMahon M; Plummer SM; Higgins LG; Penning TM; Igarashi K; Hayes JD
Carcinogenesis; 2009 Sep; 30(9):1571-80. PubMed ID: 19608619
[TBL] [Abstract][Full Text] [Related]
19. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2.
Wang XJ; Sun Z; Villeneuve NF; Zhang S; Zhao F; Li Y; Chen W; Yi X; Zheng W; Wondrak GT; Wong PK; Zhang DD
Carcinogenesis; 2008 Jun; 29(6):1235-43. PubMed ID: 18413364
[TBL] [Abstract][Full Text] [Related]
20. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy.
Zhu J; Wang H; Chen F; Fu J; Xu Y; Hou Y; Kou HH; Zhai C; Nelson MB; Zhang Q; Andersen ME; Pi J
Free Radic Biol Med; 2016 Oct; 99():544-556. PubMed ID: 27634172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
